- Home
- AYTU vs CSCI Comparison
AYTU vs CSCI Comparison
Compare AYTU & CSCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYTU
- CSCI
- Stock Information
- Founded
- AYTU N/A
- CSCI 1990
- Country
- AYTU United States
- CSCI Canada
- Employees
- AYTU N/A
- CSCI N/A
- Industry
- AYTU Biotechnology: Pharmaceutical Preparations
- CSCI
- Sector
- AYTU Health Care
- CSCI
- Exchange
- AYTU Nasdaq
- CSCI NYSE
- Market Cap
- AYTU 15.0M
- CSCI 12.5M
- IPO Year
- AYTU N/A
- CSCI 1996
- Fundamental
- Price
- AYTU $2.36
- CSCI $3.70
- Analyst Decision
- AYTU
- CSCI
- Analyst Count
- AYTU 0
- CSCI 0
- Target Price
- AYTU N/A
- CSCI N/A
- AVG Volume (30 Days)
- AYTU 29.8K
- CSCI 5.3K
- Earning Date
- AYTU 11-12-2024
- CSCI 11-07-2024
- Dividend Yield
- AYTU N/A
- CSCI N/A
- EPS Growth
- AYTU N/A
- CSCI N/A
- EPS
- AYTU N/A
- CSCI N/A
- Revenue
- AYTU $81,002,000.00
- CSCI $4,915,000.00
- Revenue This Year
- AYTU N/A
- CSCI N/A
- Revenue Next Year
- AYTU N/A
- CSCI N/A
- P/E Ratio
- AYTU N/A
- CSCI N/A
- Revenue Growth
- AYTU N/A
- CSCI N/A
- 52 Week Low
- AYTU $2.20
- CSCI $3.49
- 52 Week High
- AYTU $3.50
- CSCI $11.10
- Technical
- Relative Strength Index (RSI)
- AYTU 44.84
- CSCI N/A
- Support Level
- AYTU $2.26
- CSCI N/A
- Resistance Level
- AYTU $2.47
- CSCI N/A
- Average True Range (ATR)
- AYTU 0.15
- CSCI 0.00
- MACD
- AYTU -0.01
- CSCI 0.00
- Stochastic Oscillator
- AYTU 16.10
- CSCI 0.00
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.
About CSCI COSCIENS BIOPHARMA INC
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology.